A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a Phase 1/2 study of GB261 in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage(Phase 1), an expansion stage(Phase 2a) and Phase 2b stage where participants will be enrolled into indication-specific cohorts.
Epistemonikos ID: dfbc8945c8d59bcc05a7fb68cb65072775c1c342
First added on: May 09, 2024